Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
Indications Paroxysmal nocturnal haemoglobinuria
Focus Adverse reactions; Therapeutic Use
Acronyms ACCESS-EXT; ACCESS-EXTENSION
Sponsors Regeneron Pharmaceuticals

Most Recent Events

25 Jun 2025 Planned primary completion date changed from 5 Feb 2029 to 26 Feb 2029.
02 Jun 2025 Planned End Date changed from 5 Feb 2029 to 26 Feb 2029.
07 Dec 2024 According to Regeneron Pharmaceuticals media release , company announced positive updated result from this trial at the American Society of Hematology (ASH) 2024 Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com